Cytospire Therapeutics CEO, Natalie Mount, recognised as Woman Entrepreneur of the Year at 2025 Cancer Research Horizons Innovation and Entrepreneurship Awards

Cytospire Therapeutics is delighted to announce that Natalie Mount, our Co-Founder and CEO, won the Woman Entrepreneur of the Year award at this year’s Innovation and Entrepreneurship Awards hosted by Cancer Research Horizons, the innovation arm of Cancer Research UK.

This award celebrates the outstanding achievements of women entrepreneurs working to accelerate translation of scientific discoveries for the benefit of people affected by cancer.

We’re delighted to see this recognition of Natalie’s career to date and her dedication and success in discovering new therapeutics to address unmet medical needs.  The award also highlights the exciting science being progressed here at Cytospire, including the advances we have made in developing the next generation of immune cell engagers as treatments for cancer.

About Cytospire Therapeutics

Cytospire is developing an innovative portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells.  Our core technology allows binding and activation of both tissue/tumor and blood resident gamma delta T cells. This opens a path to safer and more efficacious targeting of well-validated antigens that are intractable to CD3 T cell engagers due to toxicity. There are broad opportunities for Cytospire’s gamma delta T cell engagers in solid and haematological malignancies, as well as in autoimmune disease. For more information, visit www.cytospire.com

Contact

Andrew Fadden
Chief Business Officer
contact@cytospiretx.com